Mar 8, 2019

Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights

Mar 1, 2019

Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights

Feb 27, 2019

Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR

Feb 11, 2019

Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer

Feb 4, 2019

Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

Dec 12, 2018

Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

Dec 3, 2018

Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition

Nov 29, 2018

Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

Nov 26, 2018

Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer

Nov 13, 2018

Oncolytics Biotech® Announces Attendance of Upcoming Conferences